Breaking News
Sort by:
Top Post
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) has approved Dupixent (dupilumab) […]
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
CHARM Therapeutics, a 3D deep learning biotechnology company discovering and developing transformational medicines, today announced […]
RVAC Medicines Announces Research Collaboration with University of Pennsylvania
RVAC Medicines, a messenger RNA (mRNA) technology company with its global headquarters in Singapore, has […]
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
Leap Therapeutics, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that […]
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of […]
Leucid Bio and Great Ormond Street Hospital Enter Commercial Agreement at New Gene Therapy Manufacturing Centre
Leucid Bio, a biotech company pursuing a differentiated approach to develop next-generation Chimeric Antigen Receptor […]
Cambrian Bio launches Amplifier Therapeutics to Develop Clinical-Stage AMPK Activator
Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, […]
Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors
Porton Advanced Solutions and Bennu Biotherapeutics have announced a strategic partnership to advance cell and […]
BIOCORP Signs With HRA Pharma for the Development of a Medical Device Innovation
BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, […]
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
VectivBio, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, and Asahi […]
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more